Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone (CV-6504) against established murine adenocarcinomas (MAC)
1996

Anti-tumor Effects of CV-6504 on Mouse Tumors

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): HJ Hussey, MC Bibby, MJ Tisdale

Primary Institution: Pharmaceutical Sciences Institute, Aston University

Hypothesis

Does CV-6504 exhibit anti-tumor activity against established murine adenocarcinomas?

Conclusion

CV-6504 shows significant anti-tumor activity against murine adenocarcinomas, particularly in inhibiting tumor growth and reversing cachexia.

Supporting Evidence

  • CV-6504 significantly inhibited tumor growth in MAC16, MAC13, and MAC26 tumors.
  • Optimal doses of CV-6504 led to a doubling of time to sacrifice due to cachexia.
  • Histological examination showed extensive necrosis in treated tumors.

Takeaway

CV-6504 is a new medicine that helps fight certain types of cancer in mice by stopping tumors from growing and helping the mice feel better.

Methodology

The study involved administering CV-6504 to mice with transplanted MAC tumors and measuring tumor growth and body weight over time.

Limitations

The study was conducted on mice, and results may not directly translate to humans.

Participant Demographics

Male NMRI mice were used in the study.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication